China’s innovative pharmaceutical sector has hit an all-time high in deal-making, with the value of out-licensing agreements totaling roughly $110 billion from January through June of this year, according to state broadcaster CCTV. The network cited data from the National Medical Products Administration in its Monday report.
By the end of June, Chinese drugmakers had entered into 81 separate licensing agreements with foreign companies — a pace that has already surpassed 80% of the entire previous year’s total deal value.
An out-licensing agreement allows one company to grant another the rights to develop, manufacture, or bring to market a pharmaceutical product or technology. In return, the licensing company typically receives an upfront payment or future payments tied to specific development milestones, which helps spread the financial risk of drug development.
The medications covered under these deals span several major medical fields, including cancer treatment, metabolic conditions, immunology, and neurological disorders. Companies based in the United States, the United Kingdom, France, and Italy were among the primary recipients of these licensing rights.
Industry analysts note that major global pharmaceutical companies are increasingly turning to Chinese-developed experimental drugs as they race to fill their product pipelines ahead of upcoming patent expirations on existing medications.
